MRP Capital Investments LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

MRP Capital Investments LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 291 shares of the biopharmaceutical company’s stock, valued at approximately $306,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. SteelPeak Wealth LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 173.0% in the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 692 shares during the period. Atria Investments Inc boosted its position in shares of Regeneron Pharmaceuticals by 12.2% during the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after buying an additional 941 shares during the period. Nordea Investment Management AB grew its stake in shares of Regeneron Pharmaceuticals by 23.2% during the first quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after buying an additional 5,495 shares during the last quarter. Tidal Investments LLC raised its holdings in shares of Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after buying an additional 711 shares during the period. Finally, Sierra Summit Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $1,011,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $1,138.81 on Thursday. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The firm has a market cap of $125.48 billion, a price-to-earnings ratio of 33.64, a PEG ratio of 3.97 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm has a 50-day simple moving average of $1,129.45 and a two-hundred day simple moving average of $1,029.70.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the prior year, the company posted $8.79 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Analysts Set New Price Targets

REGN has been the topic of several research analyst reports. Wells Fargo & Company upped their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Royal Bank of Canada reiterated an “outperform” rating and set a $1,282.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. Finally, Truist Financial reaffirmed a “buy” rating and set a $1,200.00 price target (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,111.30.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the transaction, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at $1,467,684. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,026 shares of company stock worth $11,498,705. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.